Form 4: Processa Pharma Director Young Reports Vested Shares

David Young, a Director and President of Research & Development at Processa Pharmaceuticals, reported the distribution of 49 vested restricted shares of common stock.

Summary

• David Young, a Director and President of Research & Development at Processa Pharmaceuticals, Inc. (PCSA), reported a transaction on January 1, 2026.
• The transaction involved the acquisition of 49 shares of Common Stock through the distribution of vested restricted stock units.
• The acquisition price for these shares was $0, as it represents the vesting and distribution of previously granted restricted stock units.
• Following this transaction, David Young directly beneficially owns 8,752 shares of Common Stock.
• Additionally, Young indirectly beneficially owns 1,242 shares through the Young-Plaisance Revocable Trust, 432 shares through Family Entities, and 742 shares through CorLyst, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The distribution of vested restricted stock units is a routine compensation event and does not typically indicate a change in company performance or strategic direction.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions and typically do not provide broader industry context or strategic insights. This filing reflects a standard compensation event for an executive.

Related Party Transactions

• David Young's indirect beneficial ownership includes 1,242 shares held by the Young-Plaisance Revocable Trust, 432 shares by Family Entities, and 742 shares by CorLyst, LLC.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine insider compensation event and does not represent a significant change in ownership or company fundamentals.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, David Young, Form 4, insider transaction, restricted stock units, RSU vesting, common stock, beneficial ownership